What is the most common complication of liver transplant?

What is the most common complication of liver transplant?

The most common and most clinically significant complications are arterial and venous thrombosis and stenosis, biliary disorders, fluid collections, neoplasms, and graft rejection.

Why would alpha fetoprotein be elevated?

High levels of AFP can be a sign of liver cancer or cancer of the ovaries or testicles, as well as noncancerous liver diseases such as cirrhosis and hepatitis. High AFP levels don’t always mean cancer, and normal levels don’t always rule out cancer.

What are the contraindications for a liver transplant?

Contraindications for liver transplantation include severe cardiovascular or pulmonary disease, active drug or alcohol abuse, malignancy outside the liver, sepsis, or psychosocial problems that might jeopardize patients’ abilities to follow their medical regimens after transplant.

Why would a liver transplant be denied?

The 3 most common reasons for denial of listing were patient too well (n = 82, 49.4%), medical comorbidities and/or need for medical optimization (n = 43, 25.9%) and need for addiction rehabilitation (n = 28, 16.9%).

How long does liver transplant last?

Liver transplant survival rates In general, about 75% of people who undergo liver transplant live for at least five years. That means that for every 100 people who receive a liver transplant for any reason, about 75 will live for five years and 25 will die within five years.

What is the average life expectancy after a liver transplant?

On average, most people who receive LT live for more than 10 years. Many may live for up to 20 years or more after the transplant. A study says 90% of people with transplant survive for at least 1 year, and 70% of people may live for at least 5 years after transplant.

Can a liver transplant change your personality?

Although the transplant generally has a positive effect on their psychological functioning, some patients continue to experience psychological problems (23% anxiety, 29% depression, 15% PTS) during the two years immediately after the transplant.

Can fatty liver cause elevated AFP?

Conclusion. Patients with NAFLD have higher AFP levels than those without fatty liver changes. AFP levels rise as grade of liver steatosis increases. NAFLD should be among the differential diagnosis of elevated serum AFP levels.

Is AFP a tumor marker?

Alpha-fetoprotein (AFP) is used as a tumor marker to help detect and diagnose cancers of the liver, testicles, and ovaries.

What is the most common indication for liver transplant?

The most common indications for liver transplantation in the United States are hepatitis C virus (30%) and alcoholic liver disease (18%). Other indications include the following: Idiopathic/autoimmune liver disease (12%) Primary biliary cirrhosis (10%)

What are the indications for liver transplant evaluation?

Patients should be considered for liver transplantation if they have evidence of fulminant hepatic failure, a life-threatening systemic complication of liver disease, or a liver-based metabolic defect or, more commonly, cirrhosis with complications such as hepatic encephalopathy, ascites, hepatocellular carcinoma.

Is there a cut off for alpha fetoprotein?

In a meta-analysis that included 13 studies [ 14], the upper cut-off AFP value varied widely between 20 ng/mL and 1000 ng/mL. Due to this variation between different studies, this meta-analysis was unable to suggest a single cut-off level which could be universally approved across centres.

Which is the leading cause of liver transplantation?

Hepatocellular carcinoma (HCC) is expected to become a leading cause for liver transplantation (LT) following curative treatment for hepatitis C and after more widespread acceptance of the practice of tumour down-staging for patients originally considered beyond LT criteria [ 1].

What is the post transplant survival rate for AFP?

More specifically, patients who were successfully downstaged to AFP ≤ 400 ng/mL had a similar dropout rate (10% in both groups) and post-transplant survival rates (89% vs. 78% at 3 years, P = 0.11) to patients with AFP levels persistently ≤ 400 ng/mL.